Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | PI4KA | P42356 | 2/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | XDH | P47989 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.54 |
| ▸ | AKT2 | P31751 | 3/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | NEK2 | P51955 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenine SCHEMBL27802089 | 0.84 | LMNA (0.47) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL9621210 | 0.78 | PI4KA (0.81) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL11708523 | 0.75 | HSD17B10 (0.43) | LMNAMKNK1HTTTSHRSMN1; SMN2 | |
| SCHEMBL1017724 | 0.75 | — | — | |
| Adenine SCHEMBL385842 | 0.73 | LMNA (0.92) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL1331751 | 0.73 | PI4KA (1.00) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL8111 | 0.73 | PI4KA (1.00) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL3414606 | 0.73 | PI4KA (1.00) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL29982697 | 0.73 | PI4KA (1.00) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL29466915 | 0.73 | PI4KA (1.00) | LMNAPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364417-B2 | Increased alcohol tolerance using the PntAB gene | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2019-07-30 | — | — | US | claimed |
| WO-2001077366-A1 | POSITIVE SELECTION METHOD, COMPOUNDS, HOST CELLS AND USES THEREOF | CUBIST PHARMACEUTICALS, INC. (US) | 2001-10-18 | — | — | WO | claimed |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11980609-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4360632-A2 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240124434-A1 | ATF6 INHIBITORS AND USES THEREOF | ALTOS LABS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11950599-B2 | Compositions and methods for enhanced CO2 capture and storage | CO2 Solved, LLC (US) | 2024-04-09 | — | — | US | disclosed |
| US-11939318-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240002367-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-3911647-B1 | ISOXAZOLE COMPOUND AS FXR AGONIST AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | GILEAD SCIENCES INC (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2008002678-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070038419-A1 | Method for simulating a production process of a substance | AJINOMOTO CO., INC. | 2007-02-15 | — | — | US | disclosed |
| EP-1223982-A2 | CONJUGATE FOR TREATING ATHEROMA AND OTHER DISEASES | PHARMACYCLICS, INC. (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001077366-A1 | POSITIVE SELECTION METHOD, COMPOUNDS, HOST CELLS AND USES THEREOF | CUBIST PHARMACEUTICALS, INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001032211-A2 | CONJUGATE COMPOUNDS FOR TREATING ATHEROMA AND OTHER DISEASES | PHARMACYCLICS, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| US-6180762-B1 | AN ANTIBODY SPECIFIC FOR HUMAN GLYCYRRHETINIC ACID-LIKE FACTOR WHICH IS NOT GLYCYRRHETINIC ACID OR METABOLITE; SAID FACTOR INHIBITS 11BETA-HYDROXY STEROID DEHYDROGENASE AND 5BETA-STEROID REDUCTASE; DIAGNOSING HYPERTENSION | MORRIS DAVID J (US) | 2001-01-30 | — | — | US | disclosed |
| CN-1278063-A | Electrochemical analysis using electrode coated with conductive diamond, and electrochemical analysis system therewith | MEIDENSHA ELECTRIC MFG CO LTD (JP) | 2000-12-27 | — | — | CN | disclosed |
| US-6010721-A | ENZYME INHIBITOR | THE MIRIAM HOSPITAL (US) | 2000-01-04 | — | — | US | disclosed |
| US-3964974-A | Enzymatic determination of glucose | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124434-A1 | ATF6 INHIBITORS AND USES THEREOF | ATF4, XBP1, ATF1 | LMNA 2920/4885PI4KA 838/4885PI4K2B 1067/4885 |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | LMNA 1879/4885PI4KA 272/4885PI4K2B 350/4885 |
| US-11980609-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | LMNA 1657/4885PI4KA 302/4885PI4K2B 349/4885 |
| US-20240002367-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | LMNA 1486/4885PI4KA 373/4885PI4K2B 439/4885 |
| US-11939318-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | LMNA 1162/4885PI4KA 270/4885PI4K2B 281/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | LMNA 1162/4885PI4KA 270/4885PI4K2B 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.